Sponsor

Miltenyi Biomedicine GmbH

Germany Friedrich-Ebert-Strasse 68, Moitzfeld, 51429 Bergisch Gladbach, Germany

About the sponsor

Research activity is concentrated in relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, mature B-cell neoplasms, and CD19-positive or CD20-positive B-cell malignancies. The portfolio also includes acute myeloid leukemia and pediatric as well as adult forms of aggressive B-cell disease.

Diffuse large B-cell lymphoma
Relapsed or refractory B-cell non-Hodgkin lymphoma
CD19-positive B-cell malignancies
Acute myeloid leukemia

These studies reflect a strong focus on cell therapy approaches for difficult-to-treat blood cancers, including settings with prior treatment failure.

About Specializations

Miltenyi Biomedicine GmbH runs clinical trials in conditions such as B-cell lymphoma recurrent, B-cell lymphoma refractory, Systemic scleroderma, Systemic lupus erythematosus, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

6 clinical trials

Systemic scleroderma+2

Recruiting

InvestigationalNo placebo

Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

B-cell lymphoma recurrent+1

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

Registered drugNo placebo

France

Participants:0–17 years
Substances:Cyclophosphamide
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

B-cell lymphoma recurrent+1

Recruiting

Registered drugNo placebo

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Oxaliplatin
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

Acute lymphocytic leukaemia recurrent+5

Recruiting

InvestigationalNo placebo

Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Mb-Cart20.1
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

Diffuse large B-cell lymphoma+5

Not recruiting

InvestigationalNo placebo

Study on MB-CART19.1 for Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

B-cell lymphoma recurrent+1

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Registered drugNo placebo

Croatia

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →

About the sponsor

About Specializations

Ongoing trials

6 clinical trials

Systemic scleroderma+2

Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis

B-cell lymphoma recurrent+1

Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

B-cell lymphoma recurrent+1

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Acute lymphocytic leukaemia recurrent+5

Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

Diffuse large B-cell lymphoma+5

Study on MB-CART19.1 for Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies

B-cell lymphoma recurrent+1

Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Are you running a clinical trial?

Prefer not to search? Our Concierge searches the trials for you.